Clicky

Cogent Biosciences, Inc.(COGT)

Description: Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.


Keywords: Biotechnology Cancer Clinical Medicine Disease Enzymes Gastrointestinal Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Gastrointestinal Stromal Tumors Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Advanced Gastrointestinal Stromal Tumors

Home Page: www.cogentbio.com

COGT Technical Analysis

200 Cambridge Park Drive
Cambridge, MA 02140
United States
Phone: 617 945 5576


Officers

Name Title
Mr. Andrew R. Robbins M.B.A. Pres, CEO & Director
Dr. John Edward Robinson Ph.D. Chief Scientific Officer
Dr. Jessica Sachs M.D. Chief Medical Officer
Mr. John L. Green C.A., CPA CFO & Principal Accounting Officer
Mr. Brad Barnett Chief Technology Officer
Mr. Evan D. Kearns J.D. Chief Legal Officer & Corp. Sec.
Ms. Erin Schellhammer Chief People Officer
Ms. Sara Saltzman Sr. VP of Regulatory Affairs
Mr. Dana R. Martin Pharm.D. Sr. VP of Medical Affairs & Chief Patient Officer
Brad Fell VP & Head of Medicinal Chemistry

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.4617
Price-to-Sales TTM: 1320.6301
IPO Date: 2018-03-29
Fiscal Year End: December
Full Time Employees: 121
Back to stocks